COCHAIRS:
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
Mario Sznol, Yale University, New Haven, CT

SUNDAY, OCTOBER 1

Registration
3:00 pm-8:00 pm | Metropolitan Ballroom Foyer

Welcome and Opening Keynote Lecture
6:30 pm-7:30 pm | Metropolitan Ballroom West

6:30-6:35 Welcome and Introduction of Keynote Speaker
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

6:35-7:15 Chasing T cell exhaustion
Crystal L. Mackall, Stanford University School of Medicine, Stanford, CA
7:15-7:30 Discussion / Q&A

Opening Reception
7:30 pm-9:30 pm | Metropolitan Ballroom East

MONDAY, OCTOBER 2

Continental Breakfast
7:00 am-8:00 am | Metropolitan Ballroom Centre

Plenary Session 1: T-cell Biology
Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
8:00 am-10:05 am | Metropolitan Ballroom West

8:00-8:05 Introduction
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY

8:05-8:25 Critical role for Batf3-lineage dendritic cells within the tumor microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, IL

8:25-8:35 Discussion / Q&A
In association with the Cancer Immunology (CIMM) Working Group

8:35-8:55  Intratumoral CD4 T cells: Empowering CD8 T cells to eliminate tumors
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
8:55-9:05  Discussion / Q&A

9:05-9:25  Mechanisms of immunotherapy response and resistance in pancreatic cancer
Ingunn Stromnes, University of Minnesota Medical School, Minneapolis, MN
9:25-9:35  Discussion / Q&A

9:35-9:45  Regulation of exhausted CD8⁺ T cell differentiation by IKZF transcription factors
Sinead M. Reading, Peter MacCallum Cancer Centre, Melbourne, Australia *
9:45-9:50  Discussion / Q&A

9:50-10:05  Panel Discussion

Break
10:05 am-10:25 am | Metropolitan Ballroom Foyer

Plenary Session 2: Macrophages and Myeloid Cells
Session Chair: Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MA
10:25 am-12:30 pm | Metropolitan Ballroom West

10:25-10:30  Introduction
Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MA

10:30-10:50  Immune archetypes and the shifting paradigms of myeloid biology in cancer
Matthew F. Krummel, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
10:50-11:00  Discussion / Q&A

11:00-11:20  Decoding clinically distinct multicellular circuits and myeloid phenotypes in cancer
Aaron M. Newman, Stanford University, Stanford, CA
11:20-11:30  Discussion / Q&A

11:30-11:50  Unraveling the complexities of tumor associated macrophages for anti-cancer therapy of breast cancer
Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MA
11:50-12:00  Discussion / Q&A
12:00-12:10  Lyn kinase regulates myeloid-cell responses to mammary tumors  
Joseph T. Greene, Masonic Cancer Center University of Minnesota, Minneapolis, MN*

12:10-12:15  Discussion / Q&A

12:15-12:30  Panel Discussion

Lunch on Own / Free Time
12:30 pm-2:30 pm

Plenary Session 3: Inhibitory Cells  
Session Chair: Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada  
2:30 pm-4:35 pm | Metropolitan Ballroom West

2:30-2:35  Introduction  
Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

2:35-2:55  Hyperactivated CD4+ T cells lacking FoxP3 inhibit therapeutics tumor immunity  
Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, MO

2:55-3:05  Discussion / Q&A

3:05-3:25  Inhibitory ILCs, B7-H3, and anti-tumor immunity  
Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

3:25-3:35  Discussion / Q&A

3:35-3:55  PMN-MDSC in regulation of immune suppressive microenvironment in cancer  
Dmitry Gabrilovich, AstraZeneca, Philadelphia, PA

3:55-4:05  Discussion / Q&A

4:05-4:15  Hypoxia promotes inflammatory fibroblast formation in pancreatic cancer  
Ashley M. Mello, University of Michigan, Ann Arbor, MI*

4:15-4:20  Discussion / Q&A

4:20-4:35  Panel Discussion

Poster Session A / Reception  
4:45 pm-7:00 pm | Metropolitan Ballroom East

Evening off / Dinner on own  
7:00 pm
TUESDAY, OCTOBER 3

Continental Breakfast
7:00 am-8:00 am | Metropolitan Ballroom Centre

Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Session Chair: Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, PA
8:00 am-10:05 am | Metropolitan Ballroom West

8:00-8:05 Introduction
Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, PA

8:05-8:25 Interferon modification of T cell function and response to immunotherapy
David G. Brooks, University of Toronto, Toronto, ON, Canada

8:25-8:35 Discussion / Q&A

8:35-8:55 Metabolic and neural regulation of immunity and cancer
Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

8:55-9:05 Discussion / Q&A

9:05-9:25 LAG-3: The third checkpoint inhibitor & its synergistic interactions with PD1
Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, PA

9:25-9:35 Discussion / Q&A

9:35-9:45 Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity
Lloyd Bod, Massachusetts General Hospital, Boston, MA*

9:45-9:50 Discussion / Q&A

9:50-10:05 Panel Discussion

Break
10:05 am-10:25 am | Metropolitan Ballroom Foyer

Plenary Session 5: Metabolic Modulation of Anti-tumor Immunity
Session Chair: Greg M. Delgoffe, UPMC Hillman Cancer Center, Pittsburgh, PA
10:25 am-12:30 pm | Metropolitan Ballroom West

10:25-10:30 Introduction
Greg M. Delgoffe, UPMC Hillman Cancer Center, Pittsburgh, PA
10:30-10:50  Metabolic modulation during in vitro expansion for curative adoptive cell therapy for cancer  
Greg M. Delgoffe, UPMC Hillman Cancer Center, Pittsburgh, PA
10:50-11:00  Discussion / Q&A

11:00-11:20  Obesity and immunometabolism in cancer immunotherapy  
Jeffrey Rathmell, Vanderbilt University Medical Center, Nashville, TN  
11:20-11:30  Discussion / Q&A

11:30-11:50  Tailoring T cell anti-tumor immunity via reprogramming mitochondria-guided transcription networks  
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland  
11:50-12:00  Discussion / Q&A

12:00-12:20  Dgat1 camouflages sexual dimorphism in anti-tumor CD8+ T cell immunity  
Alaa Madi, German Cancer Research Center, Heidelberg, Germany*
12:10-12:15  Discussion / Q&A

12:15-12:30  Panel Discussion

Lunch on Own / Free Time  
12:30 pm-2:30 pm

Plenary Session 6: TCR-targeted Immunotherapies  
Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA  
2:30 pm-4:35 pm | Metropolitan Ballroom West

2:30-2:35  Introduction  
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

2:35-2:55  T-cell specificity, phenotype, and dynamics: Impact on cancer immunotherapy  
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA  
2:55-3:05  Discussion / Q&A

3:05-3:25  Cancer neoantigens: From discovery to the clinic  
Nina Bhardwaj, The Tisch Cancer Institute, New York, NY  
3:25-3:35  Discussion / Q&A

3:35-3:55  Specificity matters: The breadth of endogenous and elicited anti-tumor T cell responses  
Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, TN  
3:55-4:05  Discussion / Q&A
4:05-4:15 Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division
Mary Philip, Vanderbilt University Medical Center, Nashville, TN*

4:15-4:20 Discussion / Q&A

4:20-4:35 Panel Discussion

Poster Session B / Reception
4:45 pm-7:00 pm | Metropolitan Ballroom East

Evening off / Dinner on own
7:00 pm

WEDNESDAY, OCTOBER 4

Continental Breakfast
7:00 am-8:00 am | Metropolitan Ballroom Centre

Plenary Session 7: Spatial Profiling
Session Chair: Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, NY
8:00 am-9:50 am | Metropolitan Ballroom West

8:00-8:05 Introduction
Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, NY

8:05-8:25 Identifying regulators of tumor immunity by spatial functional genomics
Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, NY
8:25-8:35 Discussion / Q&A

8:35-8:55 Recirculating tumor-specific T cell responses as biomarkers for virally driven cancers
Evan Newell, Fred Hutchinson Cancer Research Center, Seattle, WA
8:55-9:05 Discussion / Q&A

9:05-9:15 Communication is key: Understanding the modulating effect of immune cell crosstalk on T cell therapy function*
Amber K.L. Wezenaar, Princess Maxima Center, Utrecht, Netherlands
9:15-9:20 Discussion / Q&A

9:20-9:50 Panel Discussion
Break
9:50 am-10:05 am | Metropolitan Ballroom Foyer

Plenary Session 8: Synthetic Biology and Immune Cell Engineering
Session Chair: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
10:05 am-11:55 am | Metropolitan Ballroom West

10:05-10:10 Introduction
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

10:10-10:30 Gene deletions unveiled: Cracking the code for CAR T cell supremacy
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
10:30-10:40 Discussion / Q&A

10:40-11:00 ‘Ain’t no mountain high enough’: Making TCR-T cells work against solid tumors
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
11:00-11:10 Discussion / Q&A

11:10-11:30 Antigen sensitivity and functional persistence of CAR T cells
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
11:30-11:40 Discussion / Q&A

11:40-11:55 Panel Discussion

Break
11:55 am-12:10 pm | Metropolitan Ballroom Foyer

Plenary Session 9: Engineered Cytokines
Session Chair: Mario Sznol, Yale University, New Haven, CT
12:10 pm-2:00 pm | Metropolitan Ballroom West

12:10-12:15 Introduction
Mario Sznol, Yale University, New Haven, CT

12:15-12:35 PD1-IL2v: PD-1-Cis IL-2Rβγ agonism yields better T cell effectors from stem-like CD8+ T cells
Pablo Umana, Roche, Schlieren, Switzerland
12:35-12:45 Discussion / Q&A
12:45-1:05  Restricting the activity of IL-2 and IL-21 to CD8+ T cells greatly enhances their therapeutic potential
Ivana Djuretic, Asher Biotherapeutics, Inc., South San Francisco, CA
1:05-1:15  Discussion / Q&A

1:15-1:35  Challenges in cancer immunotherapy: Connecting the solutions to the problems
Mario Sznol, Yale University, New Haven, CT
1:35-1:45  Discussion / Q&A

1:45-2:00  Panel Discussion

**Closing Comments and Departure**
2:00 pm | Metropolitan Ballroom West

Mario Sznol, Yale University, New Haven, CT

* - Short talk selected from proffered abstract